ClinicalTrials.gg
RecruitingNCT07861295SAMUpdated Oct 6, 2026

Satavari and Ashoka for Menopause (SAM) Study

An interventional study of Ashoka Bark and Shatavari and Placebo in Menopause, sponsored by Vidya USA Corporation. Recruiting at 1 site in United States. Open to female participants aged 40 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Vidya USA Corporation · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 11 months after the study started (first participant enrolled Oct 2025, registered Sep 2026).
  • Started Oct 2025; still recruiting 1 year 1 month later.
Updated Oct 6, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
40 Years to 65 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 193 studies in Hot Flashes with a site in United States — 26 open to participants now, 27 under way, 2 of them phase 3. Hot Flashes · United States.

Planned enrollment
115th of 180
50 · median 84
Started
2025
with 8 others
No phase
74 of 193
16 open now
Primary completion
2026-12
later than 6 of 26 live
Registered
190th of 193
by date

Among the 193 studies in Hot Flashes with a site in United States, this one is the 115th largest by planned enrollment of the 180 interventional ones that give a count, is one of 9 that started in 2025, is one of 74 with no phase, reaches primary completion later than 6 of the 26 other live ones, and was the 190th registered.

Hot Flashes

339 studies on the registry are indexed under Hot Flashes; 56 are open to participants now.

Browse Hot Flashes studies →

Open to participants now

26 of the 193 studies in Hot Flashes with a site in United States are open now. Recruiting first, the newest first:

20 more — sign in →

All 26 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 37 Hot Flashes studies recruiting now, 13 (35%) set no upper age limit and 22 (59%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 40 Years to 65 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 193 studies in Hot Flashes with a site in United States, or all of them as a file.
02

Study summary

This 12-week randomized, placebo-controlled clinical trial will evaluate the efficacy and safety of a daily oral supplement containing Ashoka Bark and Shatavari in women experiencing menopausal symptoms. Up to 50 participants will be randomized to receive either the active supplement or placebo, with 40 participants expected to complete the study. Participants will attend visits at Weeks 0, 6, and 12, where hormone levels (FSH and estradiol), menopausal symptoms, quality of life, anxiety, cognitive function, and sleep will be assessed using validated measures. The study will also explore changes in the vaginal microbiome and monitor safety and adherence throughout the trial. The study will be conducted at MusB Research in New Port Richey, Florida.

Read the detailed description

Menopause is a natural biological transition resulting from the progressive decline of ovarian function and decreased production of estrogen and progesterone. This hormonal transition is commonly accompanied by elevations in follicle-stimulating hormone (FSH) and a wide range of symptoms, including vasomotor symptoms (hot flashes and night sweats), sleep disturbances, mood changes, cognitive complaints, fatigue, urogenital symptoms, and reductions in overall quality of life. Approximately 1.3 million women enter menopause annually in the United States, and nearly 75% experience symptoms that are moderate to severe. The resulting impact on healthcare utilization, work productivity, and quality of life contributes substantially to the national healthcare burden.

Hormonal changes associated with menopause also influence the composition of the vaginal and skin microbiomes. Declining estrogen levels are associated with reductions in Lactobacillus species, altered microbial diversity, decreased epithelial integrity, reduced skin hydration, and increased susceptibility to irritation and infection. Although these biological changes have been increasingly recognized, relatively few interventional studies have evaluated whether botanical therapies influence both menopausal symptoms and the vaginal microbial environment.

Hormone replacement therapy (HRT) remains an effective treatment for many women but is not appropriate or acceptable for all individuals because of contraindications, safety concerns, or personal preference. Consequently, there is growing interest in safe, evidence-based, non-hormonal interventions that may alleviate menopausal symptoms while minimizing treatment-related risks.

Ashoka Bark (Saraca asoca) and Shatavari (Asparagus racemosus) have been used for centuries in traditional systems of medicine to support women's reproductive and hormonal health. Both botanicals contain naturally occurring bioactive compounds with reported phytoestrogenic, antioxidant, anti-inflammatory, and adaptogenic properties that may contribute to improvements in menopausal symptoms. Preliminary evidence suggests these ingredients may support hormonal balance, emotional well-being, sleep quality, and overall quality of life; however, high-quality randomized, placebo-controlled clinical trials remain limited. Additional well-designed clinical research is needed to evaluate their efficacy and safety using standardized outcome measures and objective biological assessments.

The present study has been designed to evaluate a proprietary botanical formulation containing Ashoka Bark and Shatavari ("Beauty Within") in women experiencing menopausal symptoms. The study seeks to determine whether daily supplementation produces clinically meaningful improvements in menopausal symptom severity, hormone profiles, and health-related quality of life compared with placebo in the post-menopausal women. This randomized, placebo-controlled, 12-week clinical trial will evaluate the efficacy and safety of a daily oral supplement containing Ashoka Bark and Shatavari in women with menopausal symptoms. The primary objectives are to assess changes in serum FSH and estradiol levels and improvements in menopausal symptoms measured by the MRS, GCS, and KMI. Secondary objectives include evaluating quality of life using the MENQOL questionnaire and changes in anxiety, cognitive function, and sleep disturbance using PROMIS measures. An exploratory objective will assess changes in the vaginal microbiome following treatment.

Validated patient-reported outcome instruments, including the Menopausal Rating Scale (MRS), Greene Climacteric Scale (GCS), Kupperman Menopausal Index (KMI), Menopause-Specific Quality of Life Questionnaire (MENQOL), and Patient-Reported Outcomes Measurement Information System (PROMIS) measures, provide standardized methods for evaluating symptom severity and health-related quality of life in menopausal women. In addition, laboratory assessment of reproductive hormones, particularly FSH and estradiol, provides objective measures that complement clinical symptom assessment.

The study will be conducted at MusB Research (New Port Richey, Florida) and will randomize up to 50 participants to achieve 40 study completers (20 active treatment and 20 placebo). Participants will attend three study visits over 12 weeks: baseline (Week 0), midpoint (Week 6), and endpoint (Week 12). Assessments include informed consent, eligibility screening, blood collection for FSH and estradiol, validated symptom and quality-of-life questionnaires, safety monitoring, adherence assessment, and optional vaginal microbiome sampling. Participants will take one capsule daily containing either the active botanical formulation or placebo throughout the study.

03

Conditions studied

  • Menopause

Browse trials for

Keywords

  • Menopause
  • Postmenopausal Women
  • Menopausal Symptoms
  • Ashoka Bark
  • Saraca asoca
  • Shatavari
  • Asparagus racemosus
  • Botanical Supplement
  • Herbal Supplement
  • Non-Hormonal Therapy
  • Dietary Supplement
  • Vasomotor Symptoms
  • Hot Flashes
  • Follicle-Stimulating Hormone
  • Estradiol
  • Menopausal Rating Scale
  • Greene Climacteric Scale
  • Kupperman Menopausal Index
  • Vaginal Microbiome
  • Women's Health
  • Randomized Placebo-Controlled Trial
04

Who can participate

Ages eligible
40 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Females aged 40-65 years.
  • women in good overall health and fulfilling menopausal criteria set at the MRS score more than 5.
  • Subjects had experienced absence of regular menstrual cycle for at least 3 months.
  • Willingness to sign consent, follow protocols and regimen intake, as well as maintain normal physical activity and follow study procedures.

Exclusion criteria

Exclusion Criteria:

  • Not on Hormone Replacement Therapy (HRT) or had discontinued HRT at least 12 months before admission to the study.
  • History of breast cancer,
  • ≥ 40mg/kg².
  • Prior removal of both ovaries.
  • Pregnancy, breastfeeding, or plans for pregnancy.
  • History of breast or uterine cancer, including hyperplasia, endometrial carcinoma, or cervical neoplasia.
  • Unstable medical conditions or clinically diagnosed depression requiring treatment.
  • Self-reported drug or alcohol abuse.
  • Allergy or sensitivity to herbal ingredients.
  • Undiagnosed abnormal vaginal bleeding;
  • A bilateral hysterectomy;
  • History of chronic alcoholism,
  • Medication , or allergy to dietary supplement ingredients;
  • Acute systemic infection or abnormal laboratory values.
  • No antibiotics use in past 30 days.
  • No regular probiotics use in past 30 days.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Ashoka Bark and Shatavari Intervention Arm

    Participants assigned to this arm will receive the active investigational supplement containing Ashoka Bark (Saraca asoca) and Shatavari (Asparagus racemosus). Participants will take one capsule daily (100 mg) orally before or during a meal for 12 weeks. The intervention is intended to evaluate the effect of the botanical formulation on menopausal symptoms, hormonal measures, quality of life, and exploratory microbiome outcomes. Participants will complete scheduled study assessments, symptom tracking, safety monitoring, and adherence evaluations throughout the intervention period.

    Dietary Supplement: Ashoka Bark and Shatavari

  • Placebo comparator
    Placebo Control Arm

    Participants assigned to this arm will receive a matched placebo capsule administered orally once daily before or during a meal for 12 weeks. The placebo will be identical in appearance to the active supplement to maintain blinding. Participants will undergo the same clinical assessments, symptom evaluations, safety monitoring, and adherence assessments as the intervention arm to allow comparison of outcomes between groups.

    Other: Placebo

Interventions

  • Dietary supplementAshoka Bark and Shatavari

    The intervention is an oral botanical dietary supplement containing Ashoka Bark (Saraca asoca) and Shatavari (Asparagus racemosus) intended for the management of menopausal symptoms. Participants will consume one capsule daily (100 mg) before or during a meal for 12 weeks. The formulation is being evaluated for its potential effects on menopausal symptom severity, hormone-related measures, quality of life, and related health outcomes in postmenopausal women. The intervention will be compared with a matched placebo under randomized, double-blind study conditions. Safety, adherence, and tolerability will be monitored throughout the study period.

    Also known as: Ashoka Extract, Ashoka Bark Extract, Shatavari Extract, Saraca asoca Extract, Asparagus racemosus Extract, Beauty Within

  • OtherPlacebo

    Matched placebo capsule containing inactive ingredients, administered orally once daily before or during a meal for 12 weeks. The placebo is identical in appearance to the active Ashoka Bark and Shatavari supplement to maintain blinding of participants, investigators, and outcome assessors. The placebo contains no active botanical ingredients and is used as the comparator to evaluate the effects of the Ashoka Bark and Shatavari intervention on menopausal symptoms and related outcomes.

    Also known as: Placebo Capsule

06

What researchers measure

Primary outcomes

  1. Change in Menopausal Rating Scale total score

    Change from baseline to Week 12 in menopausal symptom severity measured using the Menopausal Rating Scale (MRS). The MRS consists of 11 items assessing menopausal symptoms. The total score ranges from 0 to 44, with higher scores indicating greater symptom severity. A decrease in MRS total score indicates improvement in menopausal symptom burden.

    Time frame: Baseline (Day 0) to Week 12 (Day 84)

  2. Change in Greene Climacteric Scale total score

    Change from baseline to Week 12 in menopausal symptom severity measured using the Greene Climacteric Scale (GCS). The total score will be calculated according to the validated scoring method for the instrument. Higher scores indicate greater menopausal symptom severity. A decrease in GCS total score indicates improvement in menopausal symptom burden.

    Time frame: Baseline (Day 0) to Week 12 (Day

  3. Change in Kupperman Menopausal Index total score

    Change from baseline to Week 12 in menopausal symptom severity measured using the Kupperman Menopausal Index (KMI). The total score is calculated according to the validated KMI scoring method. Higher scores indicate greater menopausal symptom severity. A decrease in KMI total score indicates improvement in menopausal symptom burden.

    Time frame: Baseline (Day 0) to Week 12 (Day 84)

  4. Change in serum follicle-stimulating hormone concentration

    Change from baseline to Week 12 in serum follicle-stimulating hormone (FSH) concentration. Serum FSH will be measured from blood samples collected at baseline and Week 12. The outcome will be reported as the change in FSH concentration from baseline to Week 12. Unit of Measure - mIU/mL

    Time frame: Baseline (Day 0) to Week 12 (Day 84)

  5. Change in serum estradiol concentration

    Change from baseline to Week 12 in serum estradiol concentration. Serum estradiol will be measured from blood samples collected at baseline and Week 12. The outcome will be reported as the change in estradiol concentration from baseline to Week 12. Unit of Measure - pg/mL

    Time frame: Baseline (Day 0) to Week 12 (Day 84)

Secondary outcomes

  1. Change in Menopause-Specific Quality of Life Questionnaire score

    Change from baseline to Week 12 in menopause-related quality of life measured using the Menopause-Specific Quality of Life Questionnaire (MENQOL). The score will be calculated according to the validated scoring method for the instrument. Higher scores indicate greater symptom impact and poorer menopause-related quality of life.

    Time frame: Baseline (Day 0) to Week 12 (Day 84)

  2. Change in Patient-Reported Outcomes Measurement Information System Anxiety Short Form 4a score

    Change from baseline to Week 12 in anxiety symptoms measured using the Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety Short Form 4a. The score will be reported using the instrument's standardized scoring method. Higher scores indicate greater anxiety severity.

    Time frame: Baseline (Day 0) to Week 12 (Day 84)

  3. Change in Patient-Reported Outcomes Measurement Information System Cognitive Function Abilities Short Form 4a score

    Change from baseline to Week 12 in perceived cognitive function measured using the Patient-Reported Outcomes Measurement Information System (PROMIS) Cognitive Function Abilities Short Form 4a. The score will be reported using the instrument's standardized scoring method. Higher scores indicate better perceived cognitive function.

    Time frame: Baseline (Day 0) to Week 12 (Day 84)

  4. Change in Patient-Reported Outcomes Measurement Information System Sleep Disturbance Short Form 4a score

    Change from baseline to Week 12 in sleep disturbance measured using the Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance Short Form 4a. The score will be reported using the instrument's standardized scoring method. Higher scores indicate greater sleep disturbance.

    Time frame: Baseline (Day 0) to Week 12 (Day 84)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • 1. Wallace, R. L., & Okonsky, H. (2018). Management of the perimenopause. Clinical Obstetrics and Gynecology, 61(3), 471-480 2. The current strategy in hormonal and non-hormonal management of menopause. Life, 13(3), 649 3. Correlation among four questionnaires that evaluate menopausal symptoms. Archives of Gynecology and Obstetrics, 306(2), 523-529 4. Hormonal and non- hormonal strategies for managing the perimenopausal period: A short review. Life, 14(1),131. 5. Menopause and cardiovascular disease: A comprehensive review of the pathophysiology, risk assessment, and management strategies. World Journal of Cardiovascular Diseases, 14(3), 164-180. 6. The association of menopausal hormone levels with disease progression in multiple sclerosis. 7. Comparing the efficacy of methylprednisolone pulse therapy in short-term and long-term multiple sclerosis patients: A quasi- experimental study. Multiple Sclerosis and Related Disorders, 75, 104724. 8. The efficacy of natalizumab on motor evoked potential changes in patients with 9. Pregnancy-related clinical outcomes in women with relapsing-remitting multiple sclerosis treated with teriflunomide. Multiple Sclerosis and Related Disorders, 90, 105825. 10. Supplemental digital content 11. Correlation among four questionnaires that evaluate menopausal symptoms. Menopause, 29(8), 953-958. 12. A factor analytic study of climacteric symptoms. Journal of Psychosomatic Research, 20(5), 425-430. 13. Menopause diagnostic tools. Retrieved August 13, 2025, 14. Selection of appropriate biomarkers to monitor effectiveness of ovarian function suppression in pre-menopausal patients with ER+ breast cancer. NPJ Breast Cancer, 10(1), 8. 15. Menopausal Changes in the Microbiome-A Review Focused on the Genitourinary Microbiome. Diagnostics (Basel), 13(6), 1193. 16. The current strategy in hormonal and non-hormonal therapies in menopause-A comprehensive review. Life (Basel), 13(3), 649.

Related links

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Dec 2026, 14 months after the start.

Of 67 interventional studies with no phase under Hot Flashes, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 34. This study's planned 14 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2026
First posted
Oct 6, 2026
StartActual
Oct 1, 2025
Primary completionEst.
Dec 1, 2026
CompletionEst.
Dec 15, 2026
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07861295
Lead sponsor
Vidya USA Corporation
Collaborators
MusB Research
Responsible party
Sponsor
First posted
Oct 6, 2026
Start date
Oct 1, 2025
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 15, 2026 (estimated)
Last update
Oct 6, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion